NTLA vs. BEAM
NTLA (Intellia Therapeutics, Inc.) and BEAM (Beam Therapeutics Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, NTLA returned -40.39%/yr vs -22.62%/yr for BEAM. Their 0.71 correlation means they have sometimes moved together and sometimes differently.
Performance
NTLA vs. BEAM - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, NTLA achieves a 18.80% return, which is significantly higher than BEAM's -7.94% return.
NTLA
- 1D
- -3.70%
- 1M
- -39.18%
- 6M
- -18.78%
- YTD
- 18.80%
- 1Y
- -7.05%
- 3Y*
- -36.11%
- 5Y*
- -40.39%
- 10Y*
- -5.06%
- ALL TIME*
- -6.82%
BEAM
- 1D
- -3.66%
- 1M
- -26.65%
- 6M
- -7.60%
- YTD
- -7.94%
- 1Y
- 35.53%
- 3Y*
- -3.63%
- 5Y*
- -22.62%
- 10Y*
- —
- ALL TIME*
- 0.95%
Liquidity Comparison
| Position | Avg. Volume Value (2W) | Avg. Volume Value (1M) | Avg. Volume Value (3M) |
|---|---|---|---|
| $49.96M | $71.79M | $70.50M | |
| $37.16M | $55.27M | $78.35M |
NTLA vs. BEAM - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|---|
NTLA Intellia Therapeutics, Inc. | 18.80% | -22.90% | -61.76% | -12.61% | -70.49% | 117.35% | 272.60% |
BEAM Beam Therapeutics Inc. | -7.94% | 11.77% | -8.89% | -30.40% | -50.92% | -2.39% | 240.17% |
Correlation
The correlation between NTLA and BEAM is 0.68, which is moderate. They have sometimes moved together and sometimes differently, sharing some price drivers without tracking each other closely.
| Correlation | |
|---|---|
Correlation (1Y) Focuses on recent behavior, but can change the most. | 0.68 |
Correlation (3Y) Balances recent behavior with more history. | 0.71 |
Correlation (5Y) Shows whether the relationship held over a longer period. | 0.76 |
Correlation (All Time) Calculated using the full available price history since Feb 6, 2020 | 0.71 |
The correlation between NTLA and BEAM has been stable across timeframes, ranging from 0.68 to 0.76 - a consistent structural relationship.
Fundamentals
NTLA:
$1.20B
BEAM:
$2.63B
NTLA:
-$3.51
BEAM:
-$0.63
NTLA:
18.16
BEAM:
19.99
NTLA:
2.04
BEAM:
2.26
NTLA:
$66.09M
BEAM:
$132.27M
NTLA:
-$33.92M
BEAM:
-$84.92M
NTLA:
-$299.32M
BEAM:
-$68.39M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
NTLA vs. BEAM — Risk / Return Rank
NTLA
BEAM
NTLA vs. BEAM - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Intellia Therapeutics, Inc. (NTLA) and Beam Therapeutics Inc. (BEAM). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| NTLA | BEAM | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.48 | ||
| Sortino ratioReturn per unit of downside risk | -0.59 | ||
| Omega ratioGain probability vs. loss probability | 1.08 | 1.13 | -0.05 |
| Calmar ratioReturn relative to maximum drawdown | -0.12 | 0.78 | -0.89 |
| Martin ratioReturn relative to average drawdown | -0.17 | 1.64 | -1.81 |
Loading charts...
Drawdowns
NTLA vs. BEAM - Drawdown Comparison
The maximum NTLA drawdown since its inception was -96.45%, which is greater than BEAM's maximum drawdown of -89.12%. Use the drawdown chart below to compare losses from any high point for NTLA and BEAM.
Loading charts...
Drawdown Indicators
| NTLA | BEAM | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -96.45% | -89.12% | -7.33% |
Max Drawdown (1Y)Largest decline over 1 year | -71.27% | -38.15% | -33.12% |
Max Drawdown (3Y)Largest decline over 3 years | -84.31% | -67.74% | -16.57% |
Max Drawdown (5Y)Largest decline over 5 years | -96.45% | -87.25% | -9.20% |
Max Drawdown (10Y)Largest decline over 10 years | -96.45% | — | — |
Current DrawdownCurrent decline from peak | -93.96% | -80.90% | -13.06% |
Average DrawdownAverage peak-to-trough decline | -57.56% | -60.22% | +2.66% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 48.81% | 18.14% | +30.67% |
Volatility
NTLA vs. BEAM - Volatility Comparison
Intellia Therapeutics, Inc. (NTLA) and Beam Therapeutics Inc. (BEAM) have volatilities of 18.85% and 18.78%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| NTLA | BEAM | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 18.85% | 18.78% | +0.07% |
Volatility (6M)Calculated over the trailing 6-month period | 56.80% | 49.97% | +6.83% |
Volatility (1Y)Calculated over the trailing 1-year period | 98.08% | 75.16% | +22.92% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 78.01% | 75.00% | +3.01% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 78.82% | 80.54% | -1.72% |
Dividends
NTLA vs. BEAM - Dividend Comparison
Neither NTLA nor BEAM has paid dividends to shareholders.
Financials
NTLA vs. BEAM - Financials Comparison
This section allows you to compare key financial metrics between Intellia Therapeutics, Inc. and Beam Therapeutics Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
NTLA and BEAM have a correlation of 0.68, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
NTLA has higher volatility (18.85%) compared to BEAM (18.78%). In terms of maximum drawdown, NTLA dropped -96.45% vs BEAM's -89.12%.
BEAM currently has the higher Sharpe Ratio (0.39 vs -0.08), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for NTLA and BEAM
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer